Mga Biologic Response Modifier
Mahahalagang Punto
- Ang biologic response modifiers (biologics) ay mga gamot na mula sa living organisms na tumatarget sa specific molecules na sangkot sa autoimmune o cancer processes.
- Ang TNF-alpha inhibitors (adalimumab, etanercept, infliximab) ang pinakakaraniwang biologics para sa RA, Crohn’s disease, at psoriasis.
- Sa multiple sclerosis, ginagamit ang monoclonal antibodies tulad ng ocrelizumab, natalizumab, at alemtuzumab sa piling relapsing/progressive pathways na may mahigpit na monitoring programs.
- Mandatory ang latent TB screening (tuberculin test o IGRA) bago simulan ang biologic therapy - maaaring mag-reactivate ng latent tuberculosis ang biologics.
- Malaki ang pagtaas ng infection risk sa biologics; contraindicated ang live vaccines habang ginagamot.
- Maaaring maging life-threatening ang hypersensitivity reactions sa panahon ng IV infusion - dapat may premedication at emergency equipment na available.
- May severe black-box safety risks ang rituximab at iba pang oncology biologics (fatal infusion reactions, HBV reactivation, progressive multifocal leukoencephalopathy).
- Lubhang kahalintulad ng reference biologics ang biosimilars ngunit hindi eksaktong molecular copies; bago maaprubahan, dapat maipakitang walang clinically meaningful efficacy/safety differences.
- Sa psoriasis pathways, tina-target ng ustekinumab ang IL-12/23 signaling bilang alternatibong biologic mechanism lampas sa TNF inhibition.
Mechanism Overview
Ang biologics ay engineered proteins (monoclonal antibodies, fusion proteins, o receptor constructs) na kumakapit at nagne-neutralize ng specific cytokines, receptors, o cell surface markers na kasangkot sa disease processes:
Autoimmune Biologics
| Drug (Brand) | Target | Class | Indications |
|---|---|---|---|
| Adalimumab (Humira) | TNF-alpha | Anti-TNF monoclonal antibody | RA, psoriatic arthritis, Crohn’s disease, UC, ankylosing spondylitis |
| Etanercept (Enbrel) | TNF-alpha and TNF-beta | Soluble TNF receptor fusion protein | RA, psoriatic arthritis, psoriasis, ankylosing spondylitis |
| Infliximab (Remicade) | TNF-alpha | Anti-TNF chimeric monoclonal antibody | RA, Crohn’s disease, UC, psoriasis, ankylosing spondylitis |
| Ustekinumab (Stelara) | IL-12/23 | Monoclonal antibody | Psoriasis, psoriatic arthritis, inflammatory bowel disease pathways |
| Tocilizumab (Actemra) | IL-6 receptor | Anti-IL-6R monoclonal antibody | RA (kapag nabigo ang TNF inhibitors) |
| Abatacept (Orencia) | CD80/CD86 on T cells | CTLA-4-Ig fusion protein | RA (T cell co-stimulation blockade) |
| Rituximab (Rituxan) | CD20 on B cells | Anti-CD20 monoclonal antibody | RA (kapag nabigo ang TNF inhibitors); lymphoma; SLE |
| Ocrelizumab (Ocrevus) | CD20 on B cells | Anti-CD20 monoclonal antibody | Relapsing MS at primary progressive MS pathways |
| Natalizumab (Tysabri) | Integrin-mediated leukocyte migration pathway | Monoclonal antibody | Relapsing MS kapag hindi sapat ang first-line response; major PML risk |
| Alemtuzumab (Lemtrada) | CD52 on lymphocytes | Monoclonal antibody | Highly active relapsing MS na may restricted-distribution safety program |
Cancer Biologics
| Drug | Target | Class | Indications |
|---|---|---|---|
| Pembrolizumab (Keytruda) | PD-1 on T cells | Anti-PD-1 monoclonal antibody | Melanoma, NSCLC, maraming cancers |
| Nivolumab (Opdivo) | PD-1 on T cells | Anti-PD-1 monoclonal antibody | Melanoma, lung-cancer(lung cancer), renal cell carcinoma |
| Bevacizumab (Avastin) | VEGF | Anti-VEGF monoclonal antibody | Colorectal cancer, lung cancer, glioblastoma |
| Rituximab (Rituxan) | CD20 on B cells | Anti-CD20 | Non-Hodgkin lymphoma, CLL |
Nursing Assessment
NCLEX Focus
Bago ANG ANUMANG biologic therapy, mag-screen para sa latent tuberculosis (TB skin test o IGRA). Sinasawata ng biologics ang TNF-alpha - isang pangunahing cytokine na kumokontrol sa TB granuloma integrity - at maaaring magdulot ng life-threatening TB reactivation. Kung positive ang test, kailangan munang gamutin ang TB bago simulan ang biologic therapy.
- Mag-screen para sa latent TB - kailangan bago simulan ang lahat ng TNF inhibitors.
- Suriin kung may active infection - kontraindikado ang biologics sa active serious infections.
- I-review ang hepatitis B status - HBsAg, anti-HBc (maaaring mag-reactivate ang biologics ng chronic HBV).
- Suriin para sa CHF - maaaring magpalala ang TNF inhibitors ng heart failure (contraindicated sa moderate-severe CHF).
- Suriin ang history ng demyelinating disease - maaaring magpalala ang TNF inhibitors ng multiple sclerosis.
- Sa MS monoclonal-antibody pathways, i-monitor ang bagong cognitive/visual/motor decline na maaaring magpahiwatig ng PML o iba pang severe CNS toxicity.
- Suriin ang baseline CBC at LFTs.
- Suriin ang baseline renal function at i-trend ang lipids kapag iniutos sa long-term therapy.
- Suriin ang immunization status - ibigay ang mga kinakailangang vaccines bago simulan ang biologic therapy.
Nursing Interventions
- Pre-infusion preparation: Maghanda ng emergency medications (epinephrine, diphenhydramine, corticosteroids) - maaaring mangyari ang anaphylaxis, lalo na sa unang infusion.
- Hypersensitivity monitoring during infusion: I-monitor ang vital signs; bantayan ang chills, fever, dyspnea, chest tightness, urticaria; itigil ang infusion kung may reaction.
- Sa MS infusion pathways, ipagpatuloy ang post-infusion observation ayon sa protocol (halimbawa hindi bababa sa 1-2 oras para sa maraming monoclonal regimens).
- Premedication: Ibigay ang diphenhydramine at acetaminophen bago ang rituximab at iba pang IV biologics upang mabawasan ang infusion reaction risk.
- Panatilihing madaling makuha ang emergency-response medications habang infusion (lalo na epinephrine para sa biglaang severe reactions).
- Infection surveillance: I-report agad ang anumang lagnat, ubo, sugat, o hindi karaniwang sintomas; i-hold ang biologic therapy kapag may active infection.
- Reproductive-risk counseling: I-review ang pregnancy at breastfeeding plans bago pumili ng therapy at palakasin ang specialist-directed contraception/pregnancy-risk guidance kapag naaangkop.
- Live vaccine prohibition: Ipaalam sa patients na contraindicated ang live vaccines (MMR, varicella, intranasal flu) habang biologic therapy.
- Kumpletuhin muna ang indicated VZV at iba pang live vaccines bago simulan ang therapy kung maaari; iwasan ang live vaccines pagkatapos simulan.
- Injection site teaching: Ang adalimumab at etanercept ay self-injected subcutaneously - ituro ang rotation ng injection sites, tamang storage (refrigerated), at pagkilala sa injection site reactions.
- Skin and lymph node monitoring: Pinapataas ng biologics ang panganib ng melanoma, lymphoma, at non-melanoma skin cancer - i-report agad ang bagong skin lesions.
Latent TB Reactivation Risk
Lahat ng TNF inhibitors (adalimumab, etanercept, infliximab) ay may BLACK BOX WARNING para sa reactivation ng latent tuberculosis. Dapat isagawa ang testing BAGO simulan ang therapy. Kung mag-convert ang TB tests o magpakita ng active TB symptoms ang pasyente, agad i-hold ang therapy at ipa-evaluate sa infectious disease.
Increased Infection and Malignancy Risk
Pinapahina ng biologics ang immune system at may BLACK BOX WARNINGS para sa serious infections (kabilang ang opportunistic infections gaya ng histoplasmosis, cryptococcosis, at PCP) at para sa lymphoma at iba pang malignancies.
Rituximab Severe Reactions
Maaaring magdulot ang rituximab ng fatal infusion reactions, hepatitis B reactivation, mucocutaneous reactions, at progressive multifocal leukoencephalopathy. Karaniwang pinakamataas ang panganib sa mga unang infusions.
Pharmacology Summary
| Drug | Route | Administration Notes |
|---|---|---|
| Adalimumab (Humira) | Subcutaneous injection | Every 2 weeks; self-injectable; refrigerate |
| Etanercept (Enbrel) | Subcutaneous injection | Weekly; self-injectable; refrigerate |
| Infliximab (Remicade) | IV infusion | 0, 2, 6 weeks (induction), then every 8 weeks; premedicate; monitor during infusion |
| Rituximab (Rituxan) | IV infusion | Mabagal na initial rate; taasan ayon sa protocol; premedicate; may panganib ng tumor lysis syndrome |
| Pembrolizumab (Keytruda) | IV infusion | Every 3 o 6 weeks ayon sa protocol |
| Bevacizumab (Avastin) | IV infusion | Every 2-3 weeks; i-monitor ang hypertension, wound healing impairment |
Aplikasyon ng Clinical Judgment
Clinical Scenario
Isang pasyenteng may RA ang sisimulan sa infliximab. Sa unang infusion sa ika-30 minuto, nagkaroon ang pasyente ng flushing, hives, at nag-ulat ng chest tightness. Bumagsak ang blood pressure mula 122/78 papuntang 94/62.
- Recognize Cues: Acute hypersensitivity reaction (flushing, urticaria, hypotension) habang IV biologic infusion.
- Analyze Cues: Anaphylactic reaction sa infliximab - life-threatening emergency.
- Prioritize Hypotheses: Anaphylaxis na may hemodynamic compromise ang pinakamataas na prayoridad.
- Generate Solutions: Itigil agad ang infusion; magbigay ng epinephrine; tumawag ng rapid response; ilagay sa supine position na nakaangat ang mga binti; ihanda ang IV fluids.
- Take Action: Ihinto ang infusion, magbigay ng epinephrine 0.3 mg IM, i-notify ang provider, i-monitor nang tuloy-tuloy ang vitals.
- Evaluate Outcomes: Naging stable ang blood pressure, nawala ang urticaria, at nag-normalize ang respiratory status pagkatapos ng emergency treatment.
Related Concepts
- disease modifying antirheumatic drugs - Karaniwang sinusubukan muna ang conventional DMARDs bago biologics sa karamihan ng RA treatment algorithms.
- rheumatoid arthritis autoimmune joint disease - RA ang pangunahing autoimmune indication para sa anti-TNF biologics.
- inflammatory bowel disease - Ginagamit ang infliximab at adalimumab sa Crohn’s disease at UC treatment.
- active and passive immunity - Pag-unawa sa immunosuppression mechanisms at vaccine contraindications.
- hypersensitivity types and anaphylaxis response - Infusion reactions at anaphylaxis management protocols.
Self-Check
- Bakit kailangang i-screen at gamutin ang latent tuberculosis bago simulan ang TNF inhibitor therapy?
- Anong pre-medications ang karaniwang ibinibigay bago ang rituximab infusion, at bakit?
- Ano ang mechanism kung paano ginagamot ng PD-1 inhibitors tulad ng pembrolizumab ang cancer?